Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov;2(11):EVIDe2300250.
doi: 10.1056/EVIDe2300250. Epub 2023 Oct 24.

Prior Ground: Selection of Prior Distributions When Analyzing Clinical Trial Data Using Bayesian Methods

Juned Siddique  1 , Zeynab Aghabazaz  1
Affiliations
Editorial

Prior Ground: Selection of Prior Distributions When Analyzing Clinical Trial Data Using Bayesian Methods

Juned Siddique et al. NEJM Evid. 2023 Nov.

Abstract

Increasingly, investigators are choosing to use Bayesian methods for the analysis of clinical trial data. Unlike classical statistical methods that treat model parameter values (such as treatment effects) as fixed, Bayesian methods view parameters as following a probability distribution. As we have written previously,1 by analyzing clinical trial data using Bayesian methods one can obtain quantities that may be of interest to clinicians, providers, and patients, such as the probability that a treatment effect is more or less than 0, that is, the probability that a treatment is effective.

PubMed Disclaimer

Comment on

  • A Randomized Trial of Nafamostat for Covid-19.
    Morpeth SC, Venkatesh B, Totterdell JA, McPhee GM, Mahar RK, Jones M, Bandara M, Barina LA, Basnet BK, Bowen AC, Burke AJ, Cochrane B, Denholm JT, Dhungana A, Dore GJ, Dotel R, Duffy E, Dummer J, Foo H, Gilbey TL, Hammond NE, Hudson BJ, Jha V, Jevaji PR, John O, Joshi R, Kang G, Kaur B, Kim S, Das SK, Lau JSY, Littleford R, Marsh JA, Marschner IC, Matthews G, Maze MJ, McArthur CJ, McFadyen JD, McMahon JH, McQuilten ZK, Molton J, Mora JM, Mudaliar V, Nguyen V, O'Sullivan MVN, Pant S, Park JE, Paterson DL, Price DJ, Raymond N, Rees MA, Robinson JO, Rogers BA, Ryu WS, Sasadeusz J, Shum O, Snelling TL, Sommerville C, Trask N, Lewin SR, Hills TE, Davis JS, Roberts JA, Tong SYC. Morpeth SC, et al. NEJM Evid. 2023 Nov;2(11):EVIDoa2300132. doi: 10.1056/EVIDoa2300132. Epub 2023 Oct 18. NEJM Evid. 2023. PMID: 38320527 Clinical Trial.

References

    1. Bayesian Siddique J. (re)-analyses of clinical trial data. NEJM Evid 2023;2(1). DOI: 10.1056/EVIDe2200297. - DOI - PubMed
    1. Gelman A, Hill J, Vehtari A. Regression and other stories. Cambridge, UK: Cambridge University Press, 2020.
    1. Morpeth SC, Venkatesh B, Totterdell JA, et al. A randomized trial of nafamostat for Covid-19. NEJM Evid 2023;2(11). DOI: 10.1056/EVIDoa2300132. - DOI - PubMed
    1. Quinn TM, Gaughan EE, Bruce A, et al. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: phase 1b/2a experimental study to investigate safety, pharmacokinetics and pharmacodynamics. EBioMedicine 2022;76:103856. DOI: 10.1016/j.ebiom.2022.103856. - DOI - PMC - PubMed
    1. Zhuravel SV, Khmelnitskiy OK, Burlaka OO, et al. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine 2021;41: 101169. DOI: 10.1016/j.eclinm.2021.101169. - DOI - PMC - PubMed